[The role of LH-RH analogue in benign prostatic hyperplasia].
In our study 7 patients considered high risk for any surgical and anesthetic intervention, with benign prostatic hyperplasia, whose 2 with permanent catheter, were treated for 6 months with luteinizing hormone-releasing hormone analogue. The treatment resulted in an average decrease in prostatic volume of 21.7%; reduced the serum PSA/PAP values of 52% and 43%, respectively; 4 pz improved their symptom score (1 pz removed the permanent catheter), 2pz kept stationary and 1 pz made worse. No particular side effects were presented and all patients finished the therapy. We conclude that LH-RH analogue therapy should be restricted to selected patients and then it will have to be continued for a long period of time.
Ferretti
S
S
Divisione di Urologia, USL 4, Ospedale Maggiore, Parma.
Salsi
P
P
Arena
F
F
Peracchia
G
G
Cortellini
P
P
D000368:Aged; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
D007987:Gonadotropin-Releasing Hormone